BioSpace News Archive

Drug Development

Alnylam Adds Office Space, Employees Ahead of Aug. 11 PDUFA Date for Patisiran

After a slight delay, things remain on schedule for Alnylam’s new $200 million manufacturing facility. The company expects the site to open in late 2019, which could follow regulatory approval of patisiran, its RNAi treatment for Hereditary ATTR Amyloidosis.

August 8, 2018
·
2 min read
·
Alex Keown
Genetown

SQZ Biotechnologies Closes Oversubscribed $72 Million Series C

Watertown, Massachusetts-based SQZ Biotechnologies completed an oversubscribed Series C financing worth $72 million. New investors included Everblue, Illumina Ventures, Invus, Orient Life, and Viva Ventures Biotech Group.

August 8, 2018
·
2 min read
·
Mark Terry
Policy

U.S. Rep. Chris Collins, an Innate Immunotherapeutics Board Member, Charged With Insider Trading

A New York Republican Congressman and his son have been charged with insider trading. U.S. Rep. Chris Collins was a board member for Australia-based Innate Immunotherapeutics. The government charged he used that information to help his son make timely trades.

August 8, 2018
·
2 min read
·
Alex Keown
BioCapital

A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year

Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.

August 8, 2018
·
6 min read
·
Mark Terry
Business

Pharma Companies Create Memorable Ad Campaigns for Branded Products

The pharma industry has developed ad campaigns to tout the efficacy of its branded products to consumers, often using celebrities to add his or her personal stamp onto a pharmaceutical product.

August 8, 2018
·
3 min read
·
Alex Keown